Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: A retrospective analysis

Kaohsiung Journal of Medical Sciences. 2017;33(12):609-615 DOI 10.1016/j.kjms.2017.07.002

 

Journal Homepage

Journal Title: Kaohsiung Journal of Medical Sciences

ISSN: 1607-551X (Print); 2410-8650 (Online)

Publisher: Wiley

Society/Institution: Kaohsiung Medical University

LCC Subject Category: Medicine: Medicine (General)

Country of publisher: Australia

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS

Ming-Xiong Sheng (Department of Urology, Mindong Hospital Affiliated to Fujian Medical University, Fuan, Fujian, People's Republic of China)
Ling-Ling Wan (Department of Urology, Mindong Hospital Affiliated to Fujian Medical University, Fuan, Fujian, People's Republic of China)
Chang-Ming Liu (Department of Urology, Mindong Hospital Affiliated to Fujian Medical University, Fuan, Fujian, People's Republic of China)
Chun-Xiao Liu (Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guang Dong, People's Republic of China)
Shu-Shang Chen (Department of Urology, Fuzhou General Hospital, Xiamen University, Fuzhou, Fujian, People's Republic of China)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 24 weeks

 

Abstract | Full Text

The current study is a retrospective analysis of 49 patients with bone metastatic prostate cancer: 26 receiving androgen deprivation therapy (ADT) alone versus 23 receiving cytoreductive cryosurgery of the primary tumor plus ADT treatment. Progression-free survival (PFS) was the primary outcome variable, and Cox proportional hazards regression analysis was used to identify predictors for PFS. The baseline characteristics were generally comparable between the 2 groups. Median follow-up time was 41 months (range 24–56) and 37 months (range 19–53) in ADT alone group and cryosurgery groups, respectively. Patients receiving cryosurgery had significantly longer PFS (35 vs 25 months, P = 0.0027) and time to castration resistance (36 vs 25 months, P = 0.0011). Cox multivariate analysis associated longer PFS with the following factors: cryosurgery (HR0.207, 95% CI 0.094–0.456), lower prostate specific antigen at diagnosis (≤100 ng/ml, HR0.235, 95% CI 0.072–0.763) and lower Gleason score (≤7, HR0.195, 95% CI 0.077–0.496). Cryosurgery reduced the risk of progression by 79.3%. In conclusion, cytoreductive cryosurgery of the primary tumor in patients with bone metastatic prostate cancer could reduce the risk of progression and delay time to castration-resistant prostate cancer.